Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions
- PMID: 20923623
- PMCID: PMC2951633
- DOI: 10.4088/JCP.09m05328gry
Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions
Abstract
Objective: Prior research has consistently documented a strong association between generalized anxiety disorder (GAD) and substance use disorder (SUD). Comorbidity of GAD and SUD (GAD-SUD) represents clinical challenges, as the patients' symptoms are often more severe and are frequently prolonged, making their management more complex when compared with individuals with GAD only. The purpose of this study was to examine whether individuals with GAD-SUD differ meaningfully from individuals with GAD and no SUD comorbidity (GAD-NSUD) in terms of demographic characteristics, risk factors, psychiatric comorbidity, and clinical correlates.
Method: Data were derived from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (N = 43,093). Diagnoses were made using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV Version.
Results: We found that the lifetime prevalence rate of GAD-SUD is about 2.04%, while that of GAD-NSUD is 2.10%. Individuals with GAD-SUD showed higher psychiatric comorbidity rates than those with GAD-NSUD. Treatment-seeking rates for GAD are equally low in individuals with GAD-SUD and GAD-NSUD. Both groups were as likely to receive pharmacologic treatment for anxiety.
Conclusions: The findings of our study indicate that individuals with GAD-SUD constitute half of the lifetime prevalence of GAD and that GAD-SUD is associated with high overall vulnerability for additional psychopathology, particularly in the externalizing spectrum; higher disability; and higher use of alcohol and drugs to relieve anxiety symptoms.
© Copyright 2010 Physicians Postgraduate Press, Inc.
References
-
- Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35:1747–1759. - PubMed
-
- ESEMeD/MHEDEA 2000 Investigators. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand. 2004;109:21–27. - PubMed
-
- Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:355–364. - PubMed
-
- Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on depression, anxiety, and oncology. J Clin Psychiatry. 2001;62:64–67. - PubMed
-
- Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16:162–171. - PubMed
Publication types
MeSH terms
Grants and funding
- MH076051/MH/NIMH NIH HHS/United States
- K02 DA023200/DA/NIDA NIH HHS/United States
- R01 MH076051/MH/NIMH NIH HHS/United States
- DA019606/DA/NIDA NIH HHS/United States
- DA023200/DA/NIDA NIH HHS/United States
- R01 DA020783/DA/NIDA NIH HHS/United States
- R01 AA008159/AA/NIAAA NIH HHS/United States
- Z99 AA999999/ImNIH/Intramural NIH HHS/United States
- K05AA00161/AA/NIAAA NIH HHS/United States
- K05 AA014223/AA/NIAAA NIH HHS/United States
- DA020783/DA/NIDA NIH HHS/United States
- R01 DA019606/DA/NIDA NIH HHS/United States
- R01AA08159/AA/NIAAA NIH HHS/United States
- K24 DA022412/DA/NIDA NIH HHS/United States
- K24DA022412/DA/NIDA NIH HHS/United States
- R01 DA023973/DA/NIDA NIH HHS/United States
- Z01 AA000449/ImNIH/Intramural NIH HHS/United States
